In vitro activity of Tedizolid, Dalbavancin, and Ceftobiprole against Clostridium difficile

Dana Binyamin, Orna Nitzan, Maya Azrad, Zohar Hamo, Omry Koren, Avi Peretz

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Background: Clostridium difficile (C. difficile) is a major nosocomial pathogen that colonizes in the human gut. Recently, the U.S. FDA approved three new antimicrobial agents against gram-positive bacteria: Tedizolid, Dalbavancin, and Ceftobiprole. The efficacy of these antibiotics for treatment of C. difficile infection has not been thoroughly examined. The current study aimed to examine the in vitro activity of these antibiotics against C. difficile. In addition, to compare between Dalbavancin and Ceftobiprole to antibiotics from the same class: Vancomycin and Ceftriaxone, respectively. Methods: Eighty-four C. difficile isolates were tested for susceptibility to Tedizolid, Dalbavancin, Ceftobiprole, Vancomycin, and Ceftriaxone by Etest technique in order to determine the minimum inhibitory concentration (MIC). Results: Upon comparison of the novel antibiotic agents, Dalbavancin demonstrated the lowest MIC values and ceftobiprole the highest at MIC50 (0.016, 0.38, and 1.5 μg/mL, for Dalbavancin, Tedizolid, and Ceftobiprole, respectively) and MIC90 (0.03, 0.78, and 3.17 μg/mL, respectively). Dalbavancin demonstrated significantly lower MIC50 and MIC90 values compared to Vancomycin (0.016 vs. 0.38 and 0.03 vs. 3.5, respectively) (p < 0.001) and ceftobiprole had significantly lower MIC values compare to ceftriaxone (1.5 vs. 32 and 3.17 vs. 28.8, respectively) (p < 0.001). Conclusion: Dalbavancin and Tedizolid may play a role as potential therapeutic agents for treatment of C. difficile infection. Examination of antibiotic effect on the intestinal microbiome and clinical trials are needed for more accurate results.

Original languageEnglish
Article number1256
JournalFrontiers in Microbiology
Issue numberJUN
StatePublished - 11 Jun 2018

Bibliographical note

Publisher Copyright:
© 2018 Binyamin, Nitzan, Azrad, Hamo, Koren and Peretz.


  • Ceftobiprole
  • Ceftriaxone
  • Clostridium difficile
  • Dalbavancin
  • Tedizolid
  • Vancomycin


Dive into the research topics of 'In vitro activity of Tedizolid, Dalbavancin, and Ceftobiprole against Clostridium difficile'. Together they form a unique fingerprint.

Cite this